(SYK) Stryker Corporation News & Weekly Analysis

Editorial review: Oleksii RyzhkovIndependent educational resourceEditorial standards

US | Healthcare | Medical - Devices | NYSE

Market cap$115.617B
P/E ratio31.24
Earnings / share9.65
Dividend yield1.17%
Beta0.78
Employees56,000

Company overview

Stryker Corporation (SYK) at a glance

The week in numbers

$3.56 per share
Consensus quarterly EPS

Analysts project 11.6% year-over-year earnings growth, not realized earnings.

Analysts forecast quarterly earnings above the prior-year period.

Source report
$6.58B
Consensus quarterly revenue

Analysts project 8.6% year-over-year revenue growth, not reported sales.

Analysts forecast quarterly revenue above the year-ago period.

Source report
$2.88B
Orthopaedics sales estimate

Consensus forecast indicates 28% growth versus the prior-year quarter.

Analysts estimate quarterly Orthopaedics net sales and year-over-year growth.

Source report
-2.7%
MedSurg sales change

The reported estimate is a year-over-year sales decline, not actual results.

Analysts forecast combined MedSurg and Neurotechnology sales to decline.

Source report
Sector
Healthcare
Headquarters
Kalamazoo, Michigan, United States
Chief executive
Kevin A. Lobo
Employees
56,000
Founded
1941
Exchange
NYSE
Industry
Medical - Devices
Country
US
Trading currency
USD
Official website
stryker.com
Company Overview
Read company overview

Stryker Corporation is a medical devices company in the Healthcare sector, headquartered in Kalamazoo, Michigan, United States. Led by CEO Kevin A. Lobo, the company has 56,000 employees. Its operations serve healthcare providers in the United States and internationally through its MedSurg and Neurotechnology and Orthopaedics businesses.

The MedSurg and Neurotechnology business supplies surgical equipment, endoscopic and communications systems, patient handling and safety technologies, emergency medical equipment, and intensive-care disposable products. Its offerings also include navigation systems, stroke and venous thromboembolism treatments, products for brain and open-skull procedures, and biosurgery and orthobiologic products such as synthetic bone grafts and vertebral augmentation products.

Stryker’s Orthopaedics business provides implants for joint replacement procedures involving hips, knees, shoulders, and ankles, along with products for trauma and extremities surgeries. Its portfolio includes Mako Shoulder within its smart robotics applications. The company reaches doctors, hospitals, and other healthcare facilities through its subsidiaries, branches, third-party dealers, and distributors. Founded in 1941, Stryker operates in approximately 61 countries.

Ownership & major shareholders

Stryker Corporation shares trade on NYSE under SYK. A verified breakdown of major shareholders is not included in this profile.

The week in perspective

Weekly briefing

This week’s coverage points to product-portfolio expansion as the principal potential driver, through the completed ZuriMED acquisition and Sonopet 3 clearance. However, the impending quarterly report remains the decisive near-term test: reported analyst forecasts imply growth but had modestly weaker earnings revisions, not realized results.

News balance

4 Positive1 Risk signals4 Mixed1 Context

Positive signals

Positive signals include the completed addition of ZuriMED’s commercialized rotator-cuff technology, which could broaden Stryker’s shoulder-care offering, and FDA clearance for Sonopet 3. The reported launch plan could create neurosurgery revenue opportunities if hospitals and surgical teams adopt the system. Analysts also forecast higher quarterly revenue and earnings, including strong Orthopaedics growth.

Risks to watch

Risks center on execution rather than reported operating deterioration. Sonopet 3 has no disclosed sales target or financial contribution, so uptake, hospital demand and commercialization remain unproven. Analyst EPS expectations were revised lower, with some forecasts indicating MedSurg and Neurotechnology sales could decline. Coverage also cites potential legal scrutiny, while one acquisition report is headline-only.

Developments worth following

Latest news

Source report

Consensus points to continued quarterly revenue growth

The article says Stryker’s prior quarter produced $6.59 billion of revenue, meeting revenue expectations, while earnings exceeded consensus. For the forthcoming quarter, market expectations call for 9.3% year-over-year revenue growth, and estimates were broadly maintained.

If consensus demand assumptions hold, Stryker could sustain revenue expansion; nevertheless, the figures are forecasts before results and do not establish current-quarter sales or profitability.

Read source

medtechdive.com

Headline reports completed ZuriMED acquisition

Headline-only evidence from MedTech Dive reports that Stryker completed its ZuriMED takeover and characterizes the transaction as expanding sports-medicine and shoulder-care devices. No full article text, transaction terms, timing details, or financial effects are supplied.

If integration and commercial execution succeed, the reported portfolio addition could strengthen Stryker’s shoulder and sports-medicine offering; available evidence does not quantify revenue, costs, or synergies.

Read source

Source report

Management scheduled for healthcare investor conference

Stryker announced that its president and COO, CFO, and investor-relations vice president will participate in a healthcare conference fireside chat. The company also plans a live webcast and replay of the session.

The event could provide stakeholders with management commentary on strategy and operations, but the announcement itself supplies no new demand, financial-performance, or guidance information.

Read source

Zacks

Analysts foresee growth with weaker earnings revisions

Analysts forecast quarterly earnings of $3.56 per share and revenue of $6.58 billion, both above the prior-year period. They expect Orthopaedics growth, but project a 2.7% decline for combined MedSurg and Neurotechnology sales; consensus EPS fell 0.6% over 30 days.

Forecast Orthopaedics growth could support the quarterly mix, but lower EPS revisions and an expected combined-segment decline may constrain results if analysts’ assumptions prove accurate.

Read source

Source report

ZuriMED deal adds rotator-cuff repair technology

Stryker reported completion of its acquisition of privately held ZuriMED. The deal brings the commercialized FiberLocker rotator-cuff augmentation system into Sports Medicine and is intended to broaden support for shoulder specialists across the continuum of care.

The added technology could expand Stryker’s shoulder-care addressable offering if it gains surgeon access and adoption; the announcement provides no purchase price, sales contribution, or integration milestones.

Read source

Source report

Sonopet clearance strengthens neurosurgery product narrative

Simply Wall St reports FDA 510(k) clearance for Sonopet 3, an ultrasonic bone and soft-tissue removal platform. Its commentary says hospital capital-spending pressure or underperforming acquisitions could weaken the company’s defensive-growth narrative.

Regulatory clearance may improve Stryker’s neurosurgery proposition if commercialization converts to utilization, while hospital purchasing constraints and acquisition execution could limit the benefit.

Read source

Source report

Commentary links innovation spending to cash-flow uncertainty

Simply Wall St says Sonopet 3 clearance and a reported US$400 million commitment to CMR Surgical could support future surgical revenue, while affecting the timing and scale of cash returns. It also references a Pomerantz investigation into possible securities issues.

New surgical investments could support future revenue if adoption and execution meet expectations, but capital commitments and the cited investigation may create uncertainty around cash generation and market perception.

Read source

Zacks

Earnings forecast rises despite negative surprise indicator

The report expects year-over-year increases in quarterly earnings and revenue, but says the EPS consensus declined 0.8% over 30 days. It cites a negative 0.44% Earnings ESP and a Zacks Rank of #4, while noting three earnings beats in four quarters.

Projected growth could be favorable if delivered, but lower estimates and the publisher’s negative surprise indicators leave limited support for expecting an above-consensus earnings result.

Read source

Zacks

Value comparison flags weaker relative analyst outlook

A Zacks comparison rates Stryker at Rank #4 and Value Grade D, versus stronger ratings for Phibro Animal Health. It cites Stryker’s forward P/E of 20.39, PEG ratio of 1.96, and price-to-book ratio of 4.87.

The publisher’s relative-screening assessment may temper value-oriented interest in Stryker, but it does not report a change in the company’s underlying sales, margins, or operational execution.

Read source

Zacks

Sonopet 3 clearance advances planned neurosurgery rollout

The article reports FDA 510(k) clearance for Sonopet 3, Stryker’s surgeon-informed ultrasonic removal platform. Initial clinical cases are planned before a broader commercial rollout. It says sales targets and expected financial contribution have not been disclosed.

If hospitals and surgeons adopt Sonopet 3, the rollout could generate incremental neurosurgery revenue and deepen customer relationships; adoption pace and conversion of product benefits into demand remain key uncertainties.

Read source

(SYK) Stryker Corporation Bundle

Get Full Bundle:
$17 $9
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5